Safety and efficacy of ruxolitinib in a profoundly thrombocytopenic patient with myelofibrosis
Gespeichert in:
| Veröffentlicht in: | Annals of hematology 2015-04, Vol.94 (4), p.711-712 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 712 |
|---|---|
| container_issue | 4 |
| container_start_page | 711 |
| container_title | Annals of hematology |
| container_volume | 94 |
| creator | Armstrong, C. Maung, S. W. Neary, P. McHugh, J. Enright, H. |
| description | |
| doi_str_mv | 10.1007/s00277-014-2241-7 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_1660604190</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3614366461</sourcerecordid><originalsourceid>FETCH-LOGICAL-c409t-7dd50dcd399a1da8178ee514c6401b263a21808e2d48ece34f026d22e4d928043</originalsourceid><addsrcrecordid>eNp1kEtLAzEUhYMotlZ_gBsJuB69yWReSym-oOBC3RoyediU6aQmGXT-vSmt4sa7uYt7zrmHD6FzAlcEoLoOALSqMiAso5SRrDpAU8JymkFRs0M0hSZvsiLNBJ2EsAIgtGb0GE1owUhV52SK3p6F0XHEoldYG2OlkCN2Bvvhy3U22t622PZY4I13xg296kYcl96tWyfH6Da6txJvRLS6j_jTxiVej7pzxrbeBRtO0ZERXdBn-z1Dr3e3L_OHbPF0_zi_WWSSQROzSqkClFR50wiiRJ3KaV0QJksGpKVlLiipodZUsVpLnTMDtFSUaqYaWgPLZ-hyl5tqfgw6RL5yg-_TS07KEkpgpIGkIjuVTOWC14ZvvF0LP3ICfEuU74jyRJRvifIqeS72yUO71urX8YMwCehOENKpf9f-z-t_U78BOyKBsw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1660604190</pqid></control><display><type>article</type><title>Safety and efficacy of ruxolitinib in a profoundly thrombocytopenic patient with myelofibrosis</title><source>MEDLINE</source><source>Springer Nature - Complete Springer Journals</source><creator>Armstrong, C. ; Maung, S. W. ; Neary, P. ; McHugh, J. ; Enright, H.</creator><creatorcontrib>Armstrong, C. ; Maung, S. W. ; Neary, P. ; McHugh, J. ; Enright, H.</creatorcontrib><identifier>ISSN: 0939-5555</identifier><identifier>EISSN: 1432-0584</identifier><identifier>DOI: 10.1007/s00277-014-2241-7</identifier><identifier>PMID: 25417831</identifier><language>eng</language><publisher>Berlin/Heidelberg: Springer Berlin Heidelberg</publisher><subject>Aged ; Antineoplastic Agents - therapeutic use ; Drug-Related Side Effects and Adverse Reactions ; Hematology ; Humans ; Letter to the Editor ; Male ; Medicine ; Medicine & Public Health ; Oncology ; Primary Myelofibrosis - complications ; Primary Myelofibrosis - drug therapy ; Pyrazoles - therapeutic use ; Severity of Illness Index ; Thrombocytopenia - complications ; Thrombocytopenia - drug therapy ; Treatment Outcome</subject><ispartof>Annals of hematology, 2015-04, Vol.94 (4), p.711-712</ispartof><rights>Springer-Verlag Berlin Heidelberg 2014</rights><rights>Springer-Verlag Berlin Heidelberg 2015</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c409t-7dd50dcd399a1da8178ee514c6401b263a21808e2d48ece34f026d22e4d928043</citedby><cites>FETCH-LOGICAL-c409t-7dd50dcd399a1da8178ee514c6401b263a21808e2d48ece34f026d22e4d928043</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s00277-014-2241-7$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s00277-014-2241-7$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,777,781,27905,27906,41469,42538,51300</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/25417831$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Armstrong, C.</creatorcontrib><creatorcontrib>Maung, S. W.</creatorcontrib><creatorcontrib>Neary, P.</creatorcontrib><creatorcontrib>McHugh, J.</creatorcontrib><creatorcontrib>Enright, H.</creatorcontrib><title>Safety and efficacy of ruxolitinib in a profoundly thrombocytopenic patient with myelofibrosis</title><title>Annals of hematology</title><addtitle>Ann Hematol</addtitle><addtitle>Ann Hematol</addtitle><subject>Aged</subject><subject>Antineoplastic Agents - therapeutic use</subject><subject>Drug-Related Side Effects and Adverse Reactions</subject><subject>Hematology</subject><subject>Humans</subject><subject>Letter to the Editor</subject><subject>Male</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Oncology</subject><subject>Primary Myelofibrosis - complications</subject><subject>Primary Myelofibrosis - drug therapy</subject><subject>Pyrazoles - therapeutic use</subject><subject>Severity of Illness Index</subject><subject>Thrombocytopenia - complications</subject><subject>Thrombocytopenia - drug therapy</subject><subject>Treatment Outcome</subject><issn>0939-5555</issn><issn>1432-0584</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNp1kEtLAzEUhYMotlZ_gBsJuB69yWReSym-oOBC3RoyediU6aQmGXT-vSmt4sa7uYt7zrmHD6FzAlcEoLoOALSqMiAso5SRrDpAU8JymkFRs0M0hSZvsiLNBJ2EsAIgtGb0GE1owUhV52SK3p6F0XHEoldYG2OlkCN2Bvvhy3U22t622PZY4I13xg296kYcl96tWyfH6Da6txJvRLS6j_jTxiVej7pzxrbeBRtO0ZERXdBn-z1Dr3e3L_OHbPF0_zi_WWSSQROzSqkClFR50wiiRJ3KaV0QJksGpKVlLiipodZUsVpLnTMDtFSUaqYaWgPLZ-hyl5tqfgw6RL5yg-_TS07KEkpgpIGkIjuVTOWC14ZvvF0LP3ICfEuU74jyRJRvifIqeS72yUO71urX8YMwCehOENKpf9f-z-t_U78BOyKBsw</recordid><startdate>20150401</startdate><enddate>20150401</enddate><creator>Armstrong, C.</creator><creator>Maung, S. W.</creator><creator>Neary, P.</creator><creator>McHugh, J.</creator><creator>Enright, H.</creator><general>Springer Berlin Heidelberg</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M1P</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope></search><sort><creationdate>20150401</creationdate><title>Safety and efficacy of ruxolitinib in a profoundly thrombocytopenic patient with myelofibrosis</title><author>Armstrong, C. ; Maung, S. W. ; Neary, P. ; McHugh, J. ; Enright, H.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c409t-7dd50dcd399a1da8178ee514c6401b263a21808e2d48ece34f026d22e4d928043</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2015</creationdate><topic>Aged</topic><topic>Antineoplastic Agents - therapeutic use</topic><topic>Drug-Related Side Effects and Adverse Reactions</topic><topic>Hematology</topic><topic>Humans</topic><topic>Letter to the Editor</topic><topic>Male</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Oncology</topic><topic>Primary Myelofibrosis - complications</topic><topic>Primary Myelofibrosis - drug therapy</topic><topic>Pyrazoles - therapeutic use</topic><topic>Severity of Illness Index</topic><topic>Thrombocytopenia - complications</topic><topic>Thrombocytopenia - drug therapy</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Armstrong, C.</creatorcontrib><creatorcontrib>Maung, S. W.</creatorcontrib><creatorcontrib>Neary, P.</creatorcontrib><creatorcontrib>McHugh, J.</creatorcontrib><creatorcontrib>Enright, H.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing & Allied Health Database</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><jtitle>Annals of hematology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Armstrong, C.</au><au>Maung, S. W.</au><au>Neary, P.</au><au>McHugh, J.</au><au>Enright, H.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Safety and efficacy of ruxolitinib in a profoundly thrombocytopenic patient with myelofibrosis</atitle><jtitle>Annals of hematology</jtitle><stitle>Ann Hematol</stitle><addtitle>Ann Hematol</addtitle><date>2015-04-01</date><risdate>2015</risdate><volume>94</volume><issue>4</issue><spage>711</spage><epage>712</epage><pages>711-712</pages><issn>0939-5555</issn><eissn>1432-0584</eissn><cop>Berlin/Heidelberg</cop><pub>Springer Berlin Heidelberg</pub><pmid>25417831</pmid><doi>10.1007/s00277-014-2241-7</doi><tpages>2</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0939-5555 |
| ispartof | Annals of hematology, 2015-04, Vol.94 (4), p.711-712 |
| issn | 0939-5555 1432-0584 |
| language | eng |
| recordid | cdi_proquest_journals_1660604190 |
| source | MEDLINE; Springer Nature - Complete Springer Journals |
| subjects | Aged Antineoplastic Agents - therapeutic use Drug-Related Side Effects and Adverse Reactions Hematology Humans Letter to the Editor Male Medicine Medicine & Public Health Oncology Primary Myelofibrosis - complications Primary Myelofibrosis - drug therapy Pyrazoles - therapeutic use Severity of Illness Index Thrombocytopenia - complications Thrombocytopenia - drug therapy Treatment Outcome |
| title | Safety and efficacy of ruxolitinib in a profoundly thrombocytopenic patient with myelofibrosis |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-20T09%3A40%3A54IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Safety%20and%20efficacy%20of%20ruxolitinib%20in%20a%20profoundly%20thrombocytopenic%20patient%20with%20myelofibrosis&rft.jtitle=Annals%20of%20hematology&rft.au=Armstrong,%20C.&rft.date=2015-04-01&rft.volume=94&rft.issue=4&rft.spage=711&rft.epage=712&rft.pages=711-712&rft.issn=0939-5555&rft.eissn=1432-0584&rft_id=info:doi/10.1007/s00277-014-2241-7&rft_dat=%3Cproquest_cross%3E3614366461%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1660604190&rft_id=info:pmid/25417831&rfr_iscdi=true |